Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.
Publication
, Conference
Desjardins, A; Peters, KB; Vlahovic, G; Randazzo, D; Boulton, S; Massey, WC; Lipp, ES; Herndon, JE; Healy, P; Miller, E; Karmali, RA; Friedman, HS
Published in: Journal of Clinical Oncology
May 20, 2015
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2015
Volume
33
Issue
15_suppl
Start / End Page
2067 / 2067
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Peters, K. B., Vlahovic, G., Randazzo, D., Boulton, S., Massey, W. C., … Friedman, H. S. (2015). Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. In Journal of Clinical Oncology (Vol. 33, pp. 2067–2067). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.2067
Desjardins, Annick, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Woody C. Massey, Eric S. Lipp, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.” In Journal of Clinical Oncology, 33:2067–2067. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2067.
Desjardins A, Peters KB, Vlahovic G, Randazzo D, Boulton S, Massey WC, et al. Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2067–2067.
Desjardins, Annick, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 2067–2067. Crossref, doi:10.1200/jco.2015.33.15_suppl.2067.
Desjardins A, Peters KB, Vlahovic G, Randazzo D, Boulton S, Massey WC, Lipp ES, Herndon JE, Healy P, Miller E, Karmali RA, Friedman HS. Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2067–2067.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2015
Volume
33
Issue
15_suppl
Start / End Page
2067 / 2067
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences